Navigation Links
Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
Date:8/15/2012

ed five-year, relapse-free survival when compared to radioresistant patients.

"This study validated RSI in 503 patients in two independent data sets," Torres-Roca said. "We have validated RSI in five independent cohorts totaling 621 patients, so this latest validation study, to the best of our knowledge, makes this technology the most extensively validated molecular signature in radiation oncology."

The successful transition from applying the technology to cell lines to patient application also suggests that the biological basis of cellular radiosensitivity is conserved between cell lines and patients and also across epithelial tumors, Torres-Roca said.

"We propose that RSI is a predictive biomarker of radiation therapy therapeutic benefit for patients with breast cancer," Torres-Roca said. "This novel biomarker provides an opportunity to integrate individual tumor biology with clinical decision-making in radiation oncology."


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
2. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
3. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
4. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
5. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
6. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
7. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
8. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
9. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
10. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
11. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... following is a statement by Governor Lowell Weicker, Jr., ... President of the Board of the Trust for America,s ... Hamburg, MD, to serve as Commissioner of the Food ... as a TFAH Board Member for the past five-and-a-half ...
... involvement in health care recruiting and staffing. Individuals have the choice ... or working with an established Health Career Agents office. , ... ... Career Agents now has three ways for qualified individuals to get ...
... and futurist Ray Kurzweil , described by Forbes ... Sen. Tom Harkin (D-IA), health and wellness expert ... PepsiCo Senior Vice President and Chief Scientific Officer Dr. Mehmood ... March 16th conference on Race and Reconciliation in America: ...
... is underutilized in the U.S., expert says, , , FRIDAY, ... that people with chronic kidney disease, whether young or ... (AV) fistulas, surgically created passageways between veins and arteries ... , In calling AV fistulas the "gold standard of ...
... Plastic and Reconstructive Surgeon Kouros Azar, M.D. ... National Patient Safety Awareness Week from March 8 to 14, ... Massachusetts. Patient safety and comfort are paramount to Dr. ... foot state-of-the-art facilities located at 425 Haaland Drive, Suite 200 ...
... 1st new drug for disease in 50 years , , FRIDAY, ... offer the first new treatment approved for lupus in 50 ... College London. , The 22-month study included 20 people ... disease lupus. After treatment with Rituxan, 60 percent showed significant ...
Cached Medicine News:Health News:Appointment of Margaret Hamburg to Lead FDA Lauded by Gov. Lowell Weicker, President of the Board of Trust for America's Health 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 2Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 4Health News:Dialysis Via Fistulas May Help Young or Old 2Health News:Kouros Azar, M.D. (doctorazar.com), Noted Plastic and Reconstructive Surgeon, Offers Top 10 Tips to Patients to Help Celebrate National Patient Safety Awareness Week 2
(Date:1/23/2015)... Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), ... extracorporeal cytokine adsorber to reduce deadly inflammation in ... of $385,642, net of transaction costs, in non-dilutive ... Business Tax Certificate Transfer Program sponsored by the ...
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)...  Amgen (NASDAQ: AMGN ) today announced that it will ... Tuesday, Jan. 27, 2015, after the close of the U.S. financial ... the investment community at 2 p.m. PT. Participating in the call ... chief executive officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... N.J., June 2 Medarex, Inc.,(Nasdaq: ... a Phase 1/2 trial of,ipilimumab, an investigational ... radiotherapy in patients with metastatic castration,resistant prostate ... or in combination with radiotherapy was clinically ...
... June 2 "A two-year,survival rate of ... refractory anaplastic,astrocytoma suggests a breakthrough in this ... Bogdahn, Neuro-Oncologist and Coordinating,Investigator of the Phase ... recurrent or refractory high-grade glioma, while presenting ...
Cached Medicine Technology:Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 2Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 3Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 4Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 2Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 3Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: